Researchers publish demonstration of TIMING™ and multiomics applied to clinical samples for prediction of patient response to CAR-T therapy
Scientists demonstrate the potential for applying TIMING to identify patients that are likely to respond to immunotherapy
PUBLICATION ALERT
The Journal of Clinical Investigation has published clinical data in a manuscript by scientists from one of the first companies with an approved CAR-T cell therapy, a comprehensive cancer center, the University of Houston, and CellChorus®. The publication, “Multidimensional single-cell analysis identifies a role of CD2-CD58 interactions for clinical antitumor T cell responses,” demonstrates the potential for identifying patients that are likely to respond to a form of cancer immunotherapy called chimeric antigen receptor (CAR) T-cell therapy.
CAR T-cell therapy was first granted approval by the FDA in 2017 and can be a life-saving treatment for cancer patients with leukemia. A particularly exciting feature of CAR T-cell therapy is the possibility of inducing long-lasting tumor control or even cures for certain cancers. Despite this promise, not all patients respond to CAR-T cell therapy, and some patients can experience severe side effects. It is therefore essential to identify which patients are likely to benefit.
CellChorus merges artificial intelligence with a nanowell imaging platform to evaluate how cells move, interact, and perform over time. Researchers applied the CellChorus Time-lapse Imaging In Nanowell Grids (TIMING™) platform to evaluate interactions between thousands of tumor cells and CAR-T cells that were to be infused into patients. The researchers evaluated individual cell migration, serial killing, interaction dynamics, and cytokine secretion, and then characterized the molecular properties of CAR-T cells with the best features for eradicating tumors. Collectively, this multi-omic profiling revealed that CAR-T cells work best when binding to a molecule called CD58 on the tumor cells. Leukemia patients whose tumors did not express CD58 rarely responded to CAR-T cell therapy.
Overview of dynamic single-cell analysis and multiomic profiling conducted on clinical CAR T-cell samples with the CellChorus TIMING platform. Researchers applied the TIMING platform to quantify interactions between clinical CAR-T cells and tumor cells. After applying artificial intelligence algorithms to generate a database of functional readouts for individual cells from thousands of microscopy videos, cells of interest were identified and selected to enable integrated dynamic profiling with multi-omic profiling at single-cell resolution. (TIMING: Time-lapse Imaging Microscopy In Nanowell Grids.)
A second manuscript has posted on bioRxiv from authors affiliated with the same institutions that demonstrates that migration is a feature of T cells associated with clinical responses and is associated with bioenergetically fit cells with serial killing functionality. CellChorus is delighted to have the opportunity to work with leading experts to advance CAR-T cell treatments for optimal patient benefit. Single-cell analysis has revolutionized genomics, transcriptomics and proteomics. Evaluating the functional performance of cells over time brings an important new dimension to multi-omic analysis.
About CellChorus
CellChorus is the leader in applying artificial intelligence to visually evaluate how thousands of individual immune cells, such as T cells and NK cells, perform over time. The company applies Time-lapse Imaging Microscopy in Nanowell Grids (TIMING™) with neural network-based artificial intelligence (AI) to identify cells and evaluate their activity, including how they move, activate, kill and survive. The patent-protected CellChorus platform can link TIMING data and insights with information from other analysis modalities such as single-cell RNA sequencing and flow cytometry to provide a comprehensive understanding of cellular function, state and phenotype for the life sciences industry. Please visit cellchorus.com for more information.
Company Contact:
Daniel Meyer
Chief Executive Officer
CellChorus Inc.
TIMING@cellchorus.com
SOURCE CellChorus Inc.